Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

5-fluorouracil by protracted subcutaneous infusion. A pilot study

A Zaniboni1, F Meriggi, A Alghisi

  • 1Servizio di Oncologia, Spedali Civili, Brescia, Italy.

The Journal of Infusional Chemotherapy
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy.

ESMO open·2025
Same author

The CFTR gene variants in paediatric nasal polyposis: a study in the Italian population.

Rhinology·2025
Same author

Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial.

ESMO open·2025
Same author

Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial.

ESMO open·2025
Same author

Subjective assessment and IOTA ADNEX model in evaluation of adnexal masses in patients with history of breast cancer.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2023
Same journal

Neoadjuvant chemotherapy with continuous infusion of cisplatin and 5-fluorouracil, with or without leucovorin, for locally advanced nasopharyngeal carcinoma.

The Journal of infusional chemotherapy·1996
Same journal

Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.

The Journal of infusional chemotherapy·1996
Same journal

The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.

The Journal of infusional chemotherapy·1996
Same journal

The French experience with infusional 5-FU in gastric and pancreatic cancer.

The Journal of infusional chemotherapy·1996
Same journal

Drug stability and compatibility in oncology care.

The Journal of infusional chemotherapy·1996
Same journal

Options for venous access in ambulatory care: issues in selection and management.

The Journal of infusional chemotherapy·1996
See all related articles

Long-term subcutaneous infusion of 5-fluorouracil (5-FU) is a feasible option for advanced cancers. This method showed manageable toxicity and potential efficacy, especially when venous access is difficult.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Advanced malignancies often present challenges for conventional chemotherapy delivery.
  • Limited venous access due to thrombosis or technical issues can hinder treatment options.

Purpose of the Study:

  • To assess the feasibility of delivering 5-fluorouracil (5-FU) via long-term subcutaneous infusion (SCI).
  • To evaluate the efficacy and toxicity profile of 5-FU SCI in patients with refractory advanced cancers.

Main Methods:

  • 10 patients with advanced malignancies received 5-FU (200 mg/m2/day) via SCI using an external infusor and a thoracic wall needle.
  • Treatment continued until disease progression or unacceptable toxicity.

Main Results:

Related Experiment Videos

  • Two patients (breast, colorectal cancer) achieved partial remission; two others showed >50% decrease in tumor markers.
  • Manageable toxicities included grade II-III mucositis (2 and 1 patient, respectively) and grade II diarrhea (1 patient).
  • Local skin ulceration occurred in two patients, noted as substantial but painless and manageable.

Conclusions:

  • 5-FU delivered by SCI is a feasible treatment modality for advanced cancers.
  • This administration route warrants further investigation, particularly for patients with compromised venous access.